Quantcast

Latest Biologic Stories

2014-08-28 08:27:37

-- Fujifilm's pAVEway(TM) Platform Demonstrated >25-fold Improvement in SYN-004 Expression Titers -- ROCKVILLE, Md., Aug. 28, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and FUJIFILM Diosynth Biotechnologies UK Limited (Fujifilm), announced today confirmation of exceptional results from the initial phase of cGMP manufacturing of...

2014-08-27 23:08:41

Catalent, the leading global provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products, today announced that it is collaborating with privately held Australian biomarker research company, Minomic International Limited, to develop MIL-38, an antibody drug conjugate (ADC) for prostate cancer therapy. Under the agreement, Catalent will initially produce the antibody for a clinical study with a view to larger scale production subject...

2014-08-26 08:30:16

ROCKVILLE, Md., Aug. 26, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that SYN-004, the Company's lead anti-infective product candidate for the prevention of the devastating effects of Clostridium difficile (C. difficile), will be presented at the Infectious Disease Week (IDWeek 2014(TM)) held by...

2014-08-25 08:27:20

BEIJING, Aug. 25, 2014 /PRNewswire/ -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" or the "Company"), a leading fully integrated plasma-based biopharmaceutical company in China, today announced that its wholly-owned subsidiary Guiyang Dalin Biotechnology Co., Ltd. ("Guiyang Dalin") had agreed to acquire an additional 19.84% equity interest in Guizhou Taibang Biological Products Co., Ltd ("Guizhou Taibang") from Guizhou Eakan Pharmaceutical Co., Ltd., an existing...

2014-08-20 23:08:43

The August issue of Atlantic Information Services’s Specialty Pharmacy News offers coverage of recent developments in the biosimilars specialty pharmacy segment, including the Food and Drug Administration’s recent acceptance of a biosimilar application, the first step towards approval. Washington, DC (PRWEB) August 20, 2014 Biosimilars, which are similar versions of branded biologic drugs that are approved through an abbreviated process, could reap billions in health care savings. The...

2014-08-20 08:27:31

MUMBAI, August 20, 2014 /PRNewswire/ -- Glenmark Pharmaceuticals S.A. (GPSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Limited India (GPL), announces the discovery and initiation of IND enabling studies of a novel clinical development candidate, GBR 1302, a HER2xCD3 bispecific antibody. GBR 1302 was discovered and developed by the Glenmark Biologics Research Centre located in La Chaux-de-Fonds, Switzerland. GBR 1302 is based on Glenmark's innovative BEAT antibody...

2014-08-19 23:06:34

According to new report from BCC Research,the global market for multiple sclerosis (MS) disease-modifying products reached nearly $10.9 billion in 2013. This is estimated to grow to nearly $14.2 billion by 2018 with a compound annual growth rate (CAGR) of 5.4% from 2013 through 2018. (PRWEB) August 19, 2014 BCC Research (http://www.bccresearch.com) reveals in its new report, MULTIPLE SCLEROSIS (MS) DRUGS AND BIOLOGICS: TECHNOLOGIES AND GLOBAL MARKETS, the global market for multiple...

2014-08-19 08:29:22

-- Two of Company's Anti-Infective Programs to be Presented at Highly Regarded Scientific Conference: Pertussis and C. difficile -- ROCKVILLE, Md., Aug. 19, 2014 /PRNewswire/ -- Synthetic Biologics, Inc. (NYSE MKT: SYN), a biotechnology company developing novel anti-infective biologic and drug programs targeting specific pathogens that cause serious infections and diseases, announced today that its novel C. difficile development program will be highlighted at the 54(th) Interscience...

2014-08-14 16:27:44

Company To Pursue Next Stage of Development REDWOOD CITY, Calif., Aug. 14, 2014 /PRNewswire/ -- Coherus BioSciences, Inc. ("Coherus") today announced that CHS-1420, its proposed biosimilar of adalimumab (Humira®), met the primary endpoint in a pivotal clinical pharmacokinetic (PK) similarity study that compared CHS-1420 to Humira(®) in healthy subjects. The parallel-group, single-dose study met the criteria for clinical PK similarity on all three required, prospectively defined,...

2014-08-13 08:29:18

CARLSBAD, Calif., Aug. 13, 2014 /PRNewswire/ -- Advanced Biologics announced today the acceptance for publication of a new OsteoAMP study to be published in the Journal of Spine. In the study titled, Clinical Validation of Allogeneic Morphogenetic Protein: Donor Intervariability, Terminal Irradiation and Age of Product is not Clinically Relevant, an analysis was completed looking at the effects of different variables between allograft donors that were used to process OsteoAMP which...


Word of the Day
monteith
  • A large punch-bowl of the eighteenth century, usually of silver and with a movable rim, and decorated with flutings and a scalloped edge. It was also used for cooling and carrying wine-glasses.
  • A kind of cotton handkerchief having white spots on a colored ground, the spots being produced by a chemical which discharges the color.
This word is possibly named after Monteith (Monteigh), 'an eccentric 17th-century Scotsman who wore a cloak scalloped at the hem.'
Related